THEORETICAL AND PRACTICAL ASPECTS OF GLIMEPYRIDE FEATURES (LITERATURE REVIEW)

Authors

  • Kravchun N. А. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Mysjura K. V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2013.4.06

Keywords:

Glimepyrid, type 2 diabetes mellitus

Abstract

Selection of optimal sugar therapy type 2 diabetes, which is one on the main health issues in all over the world, is the subject of special interest of researchers and clinicians. This problem is dedicated annually many publications in domestic and foreign boundary medical literature. Only for the last 3 years several are presentedEuropean and American consensus organizations for the treatment of type 2 diabetes.

References

Dedov II. Vestn RAMN 2012; 1:7-13.

IDF Diabetes Atlas Update 2012, available at: http:www.idf.org/diabetesatlas/5e/Update.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care 2012; 35(6): 1364-1379.

UK Prospective Diabetes study Group. Lancet 1998; 352:837-853.

Gaede PP , Lund-Andersen H, Parving HH, et al. N Engl Y Med 2008; 358:580-591.

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2008; 31:1-11.

Sokolova LK. Mezhdunar Med Zhurn 2011; 1(33):61-63.

Levi Y, Cobas RA, Gomes MB. Mezhdunar Med Zhurn 2012; 7(47):9-14.

American Diabetes Association. Diabetes Care 2008; 31:12-54.

Dreval’ AV. Lechenie saharnogo diabeta i soputstvujushhih zabolevanij, Moskva, 2009: 351 p.

Nathan DM, Buse JB, Davidson MB, et al. Diabetes Care 2009; 32(1): 193-203.

Kravchun NO, et al. Suchasna peroral’na antydiabetychna terapija, Harkiv, 2007: 20 p.

Jarek-Martynova IR, Bolotskaja LL. Saharnyj Diabet 2011; 4:115-119.

Reutens AT. Nat Rev Endocrinol 2010; 6:426-427.

Pozzilli P, Leslie RD, Chan J, et al. Diabetes Metab Res Rev 2010; 26: 239-244.

Pan’kiv VI. Mezhdunar Jendokrinol Zhurn 2011; 6(38):52-57.

Pan’kiv VI. Mezhdunar Jendokrinol Zhurn 2006; 4(6):49-55.

Dedov II, Shestakova MV. Saharnyj diabet, Moskva, 2003: 455 p.

Poltorak VV, Gorshunskaja MJu. Liky Ukrai’ny 2010; 6(142):82-85.

Stratton I. M, Adler AI, Neil HA, et al. BMJ 2000; 321:405-412.

Wilmot EG, Edwardson CL, Achana FA, et al. Diabetologia 2012; 55(11):2895-2905.

Balabolkin MI, Klebanova EM, Kreminskaja VM. Mezhdunar Jendokrinol Zhurn 2010; 2(26):45-52.

Skrobonskaja NA, Sokolova LK, Ostapenko TS. Simejna Medycyna 2008; 1:37-39.

Davis SN. J Diabetes Complic 2004; 18(6):367-376.

Massi-Benedetti M. Clin The 2003; 25(3):799-816.

Matsuki M, Matsuda M, Kohara K, et al. Endocr J 2007; 54(4):571-576.

Holstein A, Plaschke A, Egberts EH. Diabetes Metab Res Rev 2001; 17(6):467-473.

Overkamp D, Vol. A, Maerker E, et al. Diabetes Care 2002; 25(11):2065-2073.

Masljanko VA, Ljashuk PM, Pavlovych LB. Mizhnar Endokrynol Zhurn 2007; 5:63-64.

Mori R, Hirabara S, Hirata A, et al. Diabetes Obes Metab 2008; 10(7): 596-600.

Nedosugova AV. Mizhnar Endokrynol Zhurn 2007; 6(12):60-66.

Tron’ko ND, Efimov AS, Tkach SN. Peroral’nye saharosnizhajushhie preparaty i taktika ih primenenija, Kiev, 2002: 110 p.

Korpachev VV, Korpacheva-Zinych OV. Jevoljucija vzgljadov v diabetologii, Kiev, 2011: 224 p.

Briscoe VJ, Griffith ML, Davis SN. Expert Opin Drug Metab Toxicol 2010; 6:225-235.

Poltorak VV, Gorbenko NI. Ukr Terapevt Zhurn 2001; 3(2):27-32.

Rosenstock J, Samols E, Muchmore DB, et al. Diabetes Care 1996; 19(11):1194-1199.

Aleksandrov AA. Consilium Medicum 2002; 4(10):551-554.

Dedov II, Balabolkin MI, Mamaeva GG, et al. Insulinovaja rezistentnost’ i rol’ gormonov zhirovoj tkani v razvitii saharnogo diabeta, Moskva, 2005: 88 p.

Kabadi UM. Managed Care 2004; 6:48-59.

Kaminskij AV. Mizhnar Endokrynol Zhurn 2011; 34(2): 56-60.

Kaminskij AV. Mezhdunar Jendokrinol zhurn 2011; 7(39):60-62.

Müller G, Hartz D, Punter J, et al. Biochem Biophys Acta 1994; 1191: 267-277.

Del Guerra S, Parentini C, Bracci C, et al. Acta Diabetol 2000; 37:139-141.

UKPDS. Lancet 1998; 352:854-865.

Charpentier G, Fleury F, Kabir M, et al. Diabet Med 2001; 18(10):828-834.

Muller G. Mol Med 2000; 6:907-933.

Kihtjak OP, Neshheret OP. Eksperym ta Klinich Fiziologija i Biohimija 2011; 1:16-23.

Miki T, Nagashima K, Tashiro F, et al. Proc Natl Acad Sci 1998; 98: 10402-10406.

Haupt A, Kausch C, Dahl D, et al. Diabetes Care 2002; 25:2119-2132.

Muller G, Geisen K, Satoh Y. Biochem Biophys Acta 1994; 1191:267-277.

Pessin JE, Thurmond DC, Elmendorf JS, et al. JBiol Chem 1999; 274:2593-2596.

Ashcroft FM, Gribble FM. J Diabetes Complic 2000; 14:192-196.

Kravchun NA, et al. Primenenie amarila v kompleksnoj terapii saharnogo diabeta tipa 2 s metabolicheskim sindromom, Har’kov, 2004: 20 p.

Mychka VB, Gornostaev VV, Chazova IE. Kardiologija 2002; 4:73-77.

Kannel W. B, Agostino RB, Wilson PW, et al. Am Heart J 1990; 120: 672-676.

Haffner SM, Lehto S, Rönnemaa T, et al. N. Engl J Med 1998; 339:229-234.

Stamler J, Vaccaro O, Neaton JD, et al. Diabetes Care 1993; 16:434-444.

Malmberg K, Yusuf S, Gerstein HC, et al. Circulation 2000; 102:1014-1019.

Batrak GA, Mjasoedova SE, Muhina MF, et al. Sovremennye tehnologii v jendokrinologii (VI Vserossijskij kongress jendokrinologov): sb. tez, Moskva, 2012: 64.

Beshlieva DD, Kalashnikov VJu, Golovenko EN. Sovremennye tehnologii v jendokrinologii (VI Vserossijskij kongress jendokrinologov): sb. tez, Moskva, 2012: 72.

Sokolova LK. Mystectvo Likuvannja 2010; 10:36-38.

Dedov II. Ozhirenie. Metabolicheskij sindrom. Saharnyj diabet 2-go tipa, Moskva, 2000: 111 p.

Grundy SM, Cleeman JI , Daniels SR, et al. Circulation 2005; 112(17): 2735-2752.

Man’kovskij BN. Mystectvo Likuvannja 2005; 9:30-33.

Kaminskij AV, Kovalenko AN. Saharnyj diabet i ozhirenie: klinicheskoe rukovodstvo po diagnostike i lecheniju, Kiev, 2010: 256 p.

Ward WK, Beard JC, Halter JB, et al. Diabetes Care 1984; 7:491-502.

Umpierrez, G, Issa M, Vlajnic A. Curr Med Res Opin 2006; 22:751-759.

Bugos C, Austin M, Atherton T, et al. Diabetes Res Clin Pract 2000; 50(1):47.

Weitgasser R, Lechleitner M, Luger A, et al. Diabetes Res Clin Pract 2003; 61:13-19.

Martin S, Kolb H, Beuth J, et al. Diabetologia 2003; 46(12):1611-1617.

Scholz G, Schneider K, Knirsch W, et al. Diabetes Res Clin Pract 2001; 21:597-604.

Kabadi MU, Kabadi UM. Ann Pharmacother 2003; 37(11):1572-1576.

Tsunekawa T, Hayashi T, Suzuki Y, et al. Diabetes Care 2003; 26:285-289.

Koshiba K, Nomuro M, Nakaya Y, et al. J Med Invest 2006; 53:87-94.

Yamauchi T, Kamon J, Monokoshi Y, et al. Nat Med 2002; 8:1288-1295.

Ouchi N, Kihara S, Arita Y, et al. Biochem J 1999; 100:2473-2476.

Ozes ON, Akca H, Mayo LD, et al. Proc Natl Acad Sci 2001; 98:4660-4645.

Jain R, Police S, Phelps K, et al. Biochem J 1999; 338:737-743.

Poltorak VV, Kravchun NA, Gorshunskaja MJu. Mizhnar Endokrynol Zhurn 2011; 5(37):76-88.

Fukuen S, Iwaki M, Yasui A, et al. J Biol Chem 2005; 280:23653-23659.

Inukai K, Watanabe M, Nakashima Y, et al. Biochem Byophys Res Commun 2005; 328:484-490.

Mori Y, Komiya H, Kurokawa N, et al. Diabetes Obes Metab 2004; 6:28-34.

Riddle M. Amer J Med 2000; 108(4):15-22.

Chelim C, Jamie CB, Kenneth AL, et al. Clin The 2008; 30(10):1893-1907.

Lee TM, Chou TF, et al. J Clin Endocrinol Metab 2003; 88:531-537.

Caulfield M, O’Brien K. Clin Diabetes 2002; 20(2):81-84.

Aleksandrov AA, Bondarenko IZ, Kuharenko SS, et al. Saharnyj Diabet 2002; 4(17):18-22.

Poltorak VV, Gorbenko NI, Gorshuns’ka MJu. Ukr Med Chasopys 2002; 6(32):65-78.

Rudyk JuS. Zdorov’ja Ukrai’ny 2007; 12(1):71-73.

Fritsche A, Schweitzer MA, Haring HU. Ann Intern Med 2003; 138(12): 952-959.

Klepzig H, Kober G, Matter C, et al. Eur Heart J 1999; 20:439.

Mkrtumjan AM. Saharnyj Diabet 2000; 4:20-24.

Downloads

Published

2013-12-20

How to Cite

Kravchun N. А., & Mysjura, K. V. (2013). THEORETICAL AND PRACTICAL ASPECTS OF GLIMEPYRIDE FEATURES (LITERATURE REVIEW). Problems of Endocrine Pathology, 46(4), 47-57. https://doi.org/10.21856/j-PEP.2013.4.06